Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic biomarkers of drug response for small-molecule therapeutics targeting the RTK/Ras/PI3K, p53 or Rb pathway in glioblastoma.

CNS oncology - 1 Jan 2016

Venkatesan Subramanian, Lamfers Martine L M, Dirven Clemens M F, Leenstra Sieger

Abstract excerpt

Glioblastoma is the most deadly and frequently occurring primary malignant tumor of the central nervous system. Genomic studies have shown that mutated oncogenes and tumor suppressor genes in glioblastoma mainly occur in three pathways: the RTK/Ras/PI3K signaling, the p53 and the Rb pathways. In this review, we summarize the modulatory effects of genetic aberrations in these three pathways to drugs targeting...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Pharmacological
Share to Glioblastoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Phosphatidylinositol 3-Kinases

Share to Phosphoinositide-3 Kinase Inhibitors

Share to ras Proteins

Share to Receptor Protein-Tyrosine Kinases

Share to Retinoblastoma Protein

Source

Open in PubMed Open full text

Identifiers

PMID: 26986934
DOI: 10.2217/cns-2015-0005
PMCID: PMC6047437

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic biomarkers of drug response for small-molecule therapeutics targeting the RTK/Ras/PI3K, p53 or Rb pathway in glioblastoma.PMID 26986934Read ↗

Will kinase inhibitors make it as glioblastoma drugs?Semantic proximity Read ↗

Genetic and signaling pathway alterations in glioblastoma: relevance to novel targeted therapies.Semantic proximity Read ↗

Targeted therapy for malignant glioma patients: lessons learned and the road ahead.Semantic proximity Read ↗

Molecular targets in glioblastoma.Semantic proximity Read ↗

Key genes altered in glioblastoma based on bioinformatics (Review)Semantic proximity Read ↗

Predictive biomarkers investigated in glioblastomaSemantic proximity Read ↗

Use of personalized molecular biomarkers in the clinical care of adults with glioblastomasSemantic proximity Read ↗

Utilisation of semiconductor sequencing for the detection of predictive biomarkers in glioblastomaSemantic proximity Read ↗

Molecular targeting of glioblastoma: Drug discovery and therapiesSemantic proximity Read ↗

Functional Precision Oncology: The Next Frontier to Improve Glioblastoma Outcome?Semantic proximity Read ↗

TP53 mutated glioblastoma stem-like cell cultures are sensitive to dual mTORC1/2 inhibition while resistance in TP53 wild type cultures can be overcome by combined inhibition of mTORC1/2 and Bcl-2.Semantic proximity Read ↗

The p53 Pathway in GlioblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.